Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.70 Consensus PT from Analysts

Sight Sciences, Inc. (NASDAQ:SGHT) has earned an average rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $4.70.

Several equities analysts have recently issued reports on SGHT shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Friday, May 3rd. Piper Sandler reaffirmed a “neutral” rating and issued a $6.00 target price (up from $5.00) on shares of Sight Sciences in a report on Friday, May 3rd.

Sight Sciences Price Performance

Shares of SGHT opened at $6.67 on Monday. Sight Sciences has a fifty-two week low of $1.04 and a fifty-two week high of $9.31. The firm’s 50-day simple moving average is $6.03 and its two-hundred day simple moving average is $5.21. The stock has a market cap of $331.90 million, a PE ratio of -5.96 and a beta of 2.76. The company has a debt-to-equity ratio of 0.31, a quick ratio of 12.42 and a current ratio of 13.01.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The company had revenue of $19.27 million during the quarter, compared to analysts’ expectations of $18.34 million. Sight Sciences had a negative return on equity of 44.45% and a negative net margin of 67.18%. Analysts anticipate that Sight Sciences will post -1.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Sight Sciences

In other news, CFO Alison Bauerlein sold 13,066 shares of Sight Sciences stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $5.42, for a total value of $70,817.72. Following the completion of the sale, the chief financial officer now directly owns 413,182 shares in the company, valued at $2,239,446.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Alison Bauerlein sold 13,066 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $5.42, for a total value of $70,817.72. Following the transaction, the chief financial officer now directly owns 413,182 shares in the company, valued at approximately $2,239,446.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Paul Badawi sold 12,571 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $63,860.68. Following the sale, the chief executive officer now owns 5,750,729 shares of the company’s stock, valued at approximately $29,213,703.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,195 shares of company stock worth $244,193. Company insiders own 28.90% of the company’s stock.

Hedge Funds Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. raised its position in Sight Sciences by 25.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock worth $1,991,000 after acquiring an additional 76,549 shares during the period. Vanguard Group Inc. raised its holdings in Sight Sciences by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after purchasing an additional 81,768 shares during the period. State Board of Administration of Florida Retirement System bought a new position in Sight Sciences in the 1st quarter worth $59,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Sight Sciences by 51.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after purchasing an additional 9,106 shares in the last quarter. Finally, RTW Investments LP bought a new stake in Sight Sciences during the fourth quarter valued at about $850,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.